Related Experiment Video
Updated: Dec 18, 2025
Generation of Monoclonal Antibodies Against Natural Products
Published on: April 6, 2019
Monoclonal antibody as a potential anti-COVID-19
Leila Jahanshahlu1, Nima Rezaei2
1School of Medical, Zanjan University of Medical Sciences, Zanjan, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Zanjan, Iran.
Abstract:
Coronavirus disease 2019 (COVID-19) is expanding rapidly, which made it as one of top priorities for scientists to develop novel treatment strategies. Researchers are racing to develop treatments based on antibodies to block and/or neutralize the coronavirus in affected patients. Initially, the genetic and structural similarity of the virus to severe acute respiratory syndrome coronavirus (SARS-CoV) created the potential for understanding disease pathogenesis. Researchers have published reports of specific monoclonal antibodies against to COVID-19 (B38, H4, 47D11) and hope that this method is effective. As well as studies on patients who are plasma therapy, the patient's condition shows improvement. The evidence for these studies is very promising and demonstrates the potential of monoclonal antibody therapy as a therapeutic approach and prevention of covid-19 infection.
Insights
Monoclonal antibody therapies show promise for treating and preventing coronavirus disease 2019 (COVID-19). Studies indicate these antibody treatments are effective in neutralizing the virus and improving patient outcomes.
Area of Science:
- Virology and Immunology
- Infectious Diseases
Background:
- Coronavirus disease 2019 (COVID-19) rapidly spread globally, necessitating urgent development of effective treatments.
- The genetic and structural similarities between SARS-CoV-2 and SARS-CoV provided initial insights into disease mechanisms.
- Antibody-based therapies are being explored to block or neutralize the SARS-CoV-2 virus in infected individuals.
Purpose of the Study:
- To evaluate the potential of monoclonal antibody therapy as a treatment and preventative strategy for COVID-19.
- To assess the efficacy of specific monoclonal antibodies (e.g., B38, H4, 47D11) against SARS-CoV-2.
- To review the impact of plasma therapy on improving the condition of COVID-19 patients.
Main Methods:
- Identification and testing of specific monoclonal antibodies targeting SARS-CoV-2.
- Clinical observation and analysis of patients undergoing plasma therapy.
- Review of existing research and published reports on antibody treatments for COVID-19.
Main Results:
- Specific monoclonal antibodies (B38, H4, 47D11) have been identified and reported.
- Plasma therapy has shown positive effects, leading to patient condition improvement.
- Evidence suggests monoclonal antibody therapy is a promising approach for COVID-19.
Conclusions:
- Monoclonal antibody therapy presents a viable therapeutic and preventative option for COVID-19.
- Further research and clinical application of these antibody treatments are warranted.
- The findings support the continued development of antibody-based strategies against SARS-CoV-2.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
00:42Cross-reactivity